Paul Lawrence, Harvard Business School professor, dies at 89

The pioneering professor at Harvard Business School died November 1 at age 89.

Paul Lawrence, M.B.A. ’47, D.C.S. ’50, a Harvard Business School professor whose work on a unifying theory of organizational behavior was the subject of an article in the September-October issue of this magazine, died November 1 at the age of 89. The Donham professor of organizational behavior emeritus at the time of his death, Lawrence was a leading scholar in his field, the author of 26 books and countless articles.

An obituary appears on the Harvard Business School website.

You might also like

Three Harvard Alumni and a Former Postdoc Named MacArthur Fellows

A labor economist, an organic chemist, a physicist, and a memory researcher were honored with 2026 “genius” grants.

At Harvard’s IOP, Two Views of Diversity Get a Hearing

Professor Cornell William Brooks and Heritage Foundation president Kevin Roberts hold a lively debate on DEI and Project 2025.

Harvard Graduate Students Union Begins Strike Authorization Vote

Amid contract negotations, two unions are discussing a joint walkout this fall.

Most popular

Harvard Weathers a Year of Turmoil

The federal government has launched unprecedented actions against the University. Here’s a guide.

Lafayette’s Unexpected Gift to George Washington: Pheasants

The two birds will be on display at Harvard this summer.

Harvard Couple Aim to Cure Prion Diseases

The stakes are high for this husband and wife: one of them will die if they don’t find a cure.

Explore More From Current Issue

A smiling William C. Kirby in a suit with glasses stands outdoors, surrounded by greenery.

The president of Harvard Magazine’s Board of Directors will step down in September.

Modern building with large glass windows, surrounded by greenery and pedestrians.

A roundup of University news from the summer of 2026

A glowing bulb shape surrounded by colorful, swirling energy lines against a blue background.

Harvard researchers achieve medical breakthroughs in cancer therapy and infection control.